Compass Therapeutics (NASDAQ:CMPX) Downgraded to “Hold” Rating by Leerink Partnrs

Compass Therapeutics (NASDAQ:CMPX) was downgraded by research analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Friday,Zacks.com reports.

Several other equities research analysts have also recently commented on CMPX. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Stock Down 13.2 %

Shares of Compass Therapeutics stock opened at $1.38 on Friday. The firm has a market cap of $189.87 million, a PE ratio of -3.73 and a beta of 0.92. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34. The company’s fifty day simple moving average is $1.75 and its two-hundred day simple moving average is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, sell-side analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after acquiring an additional 71,008 shares during the period. Opaleye Management Inc. purchased a new position in Compass Therapeutics during the 1st quarter valued at about $6,277,000. CM Management LLC lifted its position in Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after acquiring an additional 185,000 shares during the period. Bank of New York Mellon Corp lifted its position in Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after acquiring an additional 31,433 shares during the period. Finally, Barclays PLC lifted its position in Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.